NR4A1 and breast cancer: Anastrozole was shown to be at least as effective as tamoxifen as first-line treatment of postmenopausal women with advanced breast cancer, although some variation in data was observed between the two individual Phase III trials (depending upon the proportion of patients whose tumours were hormone receptor-positive).